Impeding the attainment of this dream is the complex, heterogeneous nature of breast cancer, with wildly variable histology, morphology, hormone receptor and HER2 expression, progression tempo, risk of recurrence, and patterns of dissemination during metastatic recurrence, much of which affects the need for and response to systemic therapies. The gene discussed is ERBB2; the disease is breast carcinoma.